Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection

Cancer

Volumn 117, Issue 21, 2011, Pages 4878-4889

  Ding, Tong ^a,b   Xu, Jing ^a,b   Zhang, Ying ^a,b   Guo, Rong Ping ^b   Wu, Wen Chao ^a   Zhang, Shao Dan ^b   Qian, Chao Nan ^a   Zheng, Limin ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

endothelium coated tumor cluster; hepatocellular carcinoma; immunohistochemistry; metastasis; prognosis

Indexed keywords

CD34 ANTIGEN;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURGERY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM; ENDOTHELIUM COATED TUMOR CLUSTER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; ENDOTHELIUM; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM MICROMETASTASIS; PROGNOSIS; RECURRENCE;

EID: 80054819851     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26137     Document Type: Article

References (37)

1. Bruix J, Llovet JM,. Major achievements in hepatocellular carcinoma. Lancet. 2009; 373: 614-616.
2. Yang JD, Roberts LR,. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010; 7: 448-458.
3. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-1236. (Pubitemid 43112690)
4. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006; 10: 99-111. (Pubitemid 44202603)
5. Sahai E,. Illuminating the metastatic process. Nat Rev Cancer. 2007; 7: 737-749. (Pubitemid 47463672)
6. Steeg PS,. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006; 12: 895-904. (Pubitemid 44175140)
7. Nguyen DX, Bos PD, Massague J,. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009; 9: 274-284.
8. Fidler IJ, Kripke ML,. Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat Genet. 2003; 34: 23. (Pubitemid 36548782)
9. Molnar B, Ladanyi A, Tanko L, Sreter L, Tulassay Z,. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res. 2001; 7: 4080-4085. (Pubitemid 34044631)
10. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP,. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007; 43: 979-992. (Pubitemid 46483030)
11. Sugino T, Yamaguchi T, Ogura G, et al. The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway. J Pathol. 2007; 212: 152-160. (Pubitemid 46852093)
12. Sugino T, Yamaguchi T, Ogura G, et al. Morphological evidence for an invasion-independent metastasis pathway exists in multiple human cancers [serial online]. BMC Med. 2004; 2: 9.
13. Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009; 50: 980-989.
14. Ding T, Xu J, Wang F, et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol. 2009; 40: 381-389.
15. Kuang DM, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009; 192: 1027-1034.
16. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007; 25: 2586-2593. (Pubitemid 47041232)
17. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M,. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007; 245: 909-922. (Pubitemid 46809293)
18. Zhu XD, Zhang JB, Zhuang PY, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008; 26: 2707-2716.
19. Li YW, Qiu SJ, Fan J, et al. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol. 2011; 54: 497-505.
20. Shi M, Guo RP, Lin XJ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007; 245: 36-43. (Pubitemid 46035433)
21. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006; 243: 321-328. (Pubitemid 43327762)
22. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100: 698-711.
23. Yao X, Qian CN, Zhang ZF, et al. Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin Cancer Res. 2007; 13: 161-169. (Pubitemid 46121865)
24. Kats-Ugurlu G, Roodink I, de Weijert M, et al. Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol. 2009; 219: 287-293.
25. Zhu ZH, Sun BY, Ma Y, et al. Three immunomarker support vector machines-based prognostic classifiers for stage IB nonsmall-cell lung cancer. J Clin Oncol. 2009; 27: 1091-1099.
26. Sumie S, Kuromatsu R, Okuda K, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol. 2008; 15: 1375-1382.
27. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009; 10: 35-43.
28. Garrity MM, Burgart LJ, Mahoney MR, et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol. 2004; 22: 1572-1582. (Pubitemid 41079794)
29. Urruticoechea A, Smith IE, Dowsett M,. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005; 23: 7212-7220.
30. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 2003; 361: 923-929. (Pubitemid 36332108)
31. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008; 359: 1995-2004.
32. Kusters B, Kats G, Roodink I, et al. Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis. Oncogene. 2007; 26: 5808-5815. (Pubitemid 47312812)
33. Cavallaro U, Christofori G,. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004; 4: 118-132. (Pubitemid 38198740)
34. Sawada K, Mitra AK, Radjabi AR, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008; 68: 2329-2339. (Pubitemid 351521807)
35. Trivella M, Pezzella F, Pastorino U, Harris AL, Altman DG,. Microvessel density as a prognostic factor in nonsmall-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol. 2007; 8: 488-499. (Pubitemid 46805904)
36. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ,. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med. 2000; 6: 100-102. (Pubitemid 30048535)
37. Berezovskaya O, Schimmer AD, Glinskii AB, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. 2005; 65: 2378-2386. (Pubitemid 40490149)